Skip to content

Champions Oncology, Inc.

CSBR· NasdaqCore metricsCIK 771856
Last sale
Sep 18, 2026 · +11.36%
Market cap
$76.41M
13.92M shares
Filings
659
$15.23M
Q1 2027+4.4% FY26 yoy
-$426.00K
Q1 2027N/M FY26 yoy
-$409.00K
Q1 2027N/M FY26 yoy
-$547.00K
Q1 2027derivedN/M FY26 yoy
-$0.08
FY 2026N/M FY26 yoy
$4.36M
Q1 2027−50.2% FY26 yoy
$76.41M
—
1.3×
19.6×
-8.03%
—

Twelve months to Jul 31, 2026 · derived

Price

$5.4917.07%$1.13past year
Sep 18, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$59.43MFY 2026
$59.43M0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
PeriodEndedValueKindSource trail
FY 20262026-04-30$59,425,000reported
FY 20252025-04-30$56,944,000reported
FY 20242024-04-30$50,155,000reported
FY 20232023-04-30$53,870,000reported
FY 20222022-04-30$49,109,000reported
FY 20212021-04-30$41,040,000reported
FY 20202020-04-30$32,123,000reported
FY 20192019-04-30$27,067,000reported
FY 20182018-04-30$20,241,000reported

Capital returns

Dividends and buybacks · FY2011 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—13.78M sh+1.3%0.0%
FY2024—$634.00K$634.00K—13.59M sh+1.0%—
FY2023—$74.00K$74.00K—13.46M sh−0.5%6.7%
FY2022—$0.00$0.00—13.52M sh+0.8%0.0%
FY2012—$0.00$0.00—47.07M sh+39.0%—

Segments

Products
Revenue by Products, FY2020 to FY2026FY2020Pharmacology services · FY2020 · $31.26MOther TOS revenue · FY2020 · $71.00KPersonalized oncology services · FY2020 · $790.00KFY2021Pharmacology services · FY2021 · $39.47MOther TOS revenue · FY2021 · $1.40MPersonalized oncology services · FY2021 · $166.00KFY2022Pharmacology services · FY2022 · $46.83MOther TOS revenue · FY2022 · $2.23MPersonalized oncology services · FY2022 · $49.00KFY2023Pharmacology services · FY2023 · $50.71MOther TOS revenue · FY2023 · $3.05MOther TOS revenue · FY2023 · $3.05MPersonalized oncology services · FY2023 · $116.00KFY2024Pharmacology services · FY2024 · $47.04MOther TOS revenue · FY2024 · $3.10MPersonalized oncology services · FY2024 · $18.00KFY2025Pharmacology services · FY2025 · $48.59MOther TOS revenue · FY2025 · $3.68MTOS data license revenue · FY2025 · $4.68MTOS data license revenue · FY2025 · $4.68MFY2026Pharmacology services · FY2026 · $57.13MOther TOS revenue · FY2026 · $1.53MTOS data license revenue · FY2026 · $764.00K
LineFY2026ShareChange
Pharmacology services$57.13M96%+17.6%
Other TOS revenue$1.53M2.6%−58.5%
TOS data license revenue$764.00K1.3%−83.7%
Other TOS revenue———
Personalized oncology services———
TOS data license revenue———
Total$59.43M

From the 10-K filed Jul 27, 2026CSBR

Champions Oncology, Inc. · CIK 771856 · Engraved from SEC EDGAR